PCM
MCRB icon

Prelude Capital Management’s Seres Therapeutics MCRB Stock Holding History

Prelude Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,530
Closed -$54.6K – 1384
2024
Q1 		$54.6K Buy
+3,530
New +$76.1K ﹤0.01% 1252

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's MCRB Position: Q2 2024 in Review

Prelude Capital Management sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 3,530 shares — an estimated $54.6K sold.

Prelude Capital Management first reported a position in MCRB in Q1 2024 and held it in 1 quarter. The position peaked at $54.6K in Q1 2024. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • Prelude Capital Management reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 3,530 Seres Therapeutics shares in Q2 2024, an estimated $54.6K.
  • Prelude Capital Management first reported a position in Seres Therapeutics in Q1 2024 and held it in 1 quarter.
  • Prelude Capital Management's Seres Therapeutics position peaked at $54.6K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.